These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26600051)

  • 41. Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan.
    Ho LT; Yin WH; Chuang SY; Tseng WK; Wu YW; Hsieh IC; Lin TH; Li YH; Huang LC; Wang KY; Ueng KC; Fang CC; Pan WH; Yeh HI; Wu CC; Chen JW;
    PLoS One; 2015; 10(3):e0116513. PubMed ID: 25756522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Statins for treatment of chronic liver disease.
    Marrache MK; Rockey DC
    Curr Opin Gastroenterol; 2021 May; 37(3):200-207. PubMed ID: 33654016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing statin treatment for primary prevention of coronary artery disease.
    Hayward RA; Krumholz HM; Zulman DM; Timbie JW; Vijan S
    Ann Intern Med; 2010 Jan; 152(2):69-77. PubMed ID: 20083825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationships between use of statins and arterial stiffness in normotensive and hypertensive patients with coronary artery disease.
    Wang ZG; Chen BW; Lü NQ; Cheng YM; Dang AM
    Chin Med J (Engl); 2013 Aug; 126(16):3087-92. PubMed ID: 23981617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.
    Karimi S; Hough A; Beckey C; Parra D
    J Manag Care Pharm; 2010 Sep; 16(7):472-81. PubMed ID: 20726676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk stratification for the prevention of cardiovascular complications of hypertension.
    Girerd X; Giral P
    Curr Med Res Opin; 2004 Jul; 20(7):1137-42. PubMed ID: 15265258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Appropriateness of statins in patients aged ≥80 years and comparison to other age groups.
    Chokshi NP; Messerli FH; Sutin D; Supariwala AA; Shah NR
    Am J Cardiol; 2012 Nov; 110(10):1477-81. PubMed ID: 22901970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery.
    Thielmann M; Neuhäuser M; Marr A; Jaeger BR; Wendt D; Schuetze B; Kamler M; Massoudy P; Erbel R; Jakob H
    J Thorac Cardiovasc Surg; 2007 Nov; 134(5):1143-9. PubMed ID: 17976441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy.
    Egom EE; Rose RA; Neyses L; Soran H; Cleland JG; Mamas MA
    Crit Rev Clin Lab Sci; 2013; 50(3):79-89. PubMed ID: 23885725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.
    Kamal S; Khan MA; Seth A; Cholankeril G; Gupta D; Singh U; Kamal F; Howden CW; Stave C; Nair S; Satapathy SK; Ahmed A
    Am J Gastroenterol; 2017 Oct; 112(10):1495-1505. PubMed ID: 28585556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis.
    Moctezuma-Velázquez C; Abraldes JG; Montano-Loza AJ
    Curr Treat Options Gastroenterol; 2018 Jun; 16(2):226-240. PubMed ID: 29572618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cirrhosis as new indication for statins.
    Bosch J; Gracia-Sancho J; Abraldes JG
    Gut; 2020 May; 69(5):953-962. PubMed ID: 32139553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rationale for the use of statins in liver disease.
    Schierwagen R; Uschner FE; Magdaleno F; Klein S; Trebicka J
    Am J Physiol Gastrointest Liver Physiol; 2017 May; 312(5):G407-G412. PubMed ID: 28280144
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Statins in Cirrhosis: The Magic Pill?
    Malizia G; D'Amico G
    Hepatology; 2016 Jun; 63(6):2047-9. PubMed ID: 27113274
    [No Abstract]   [Full Text] [Related]  

  • 57. [Statins: hepatotoxicity and monitoring].
    Cadranel JF; Seddik M; Loric S; Jeanne S
    Presse Med; 2009 May; 38(5):717-25. PubMed ID: 19111435
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk.
    Riley P; Al Bakir M; O'Donohue J; Crook M
    Cardiovasc Ther; 2009; 27(3):216-20. PubMed ID: 19555426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effect of the administration of statins in non-cardiac critical disease].
    Ruiz-Bailén M; Pérez-Valenzuela J; Ferrezuelo-Mata A; Obra-Cuadra RJ
    Med Intensiva; 2011 Mar; 35(2):107-16. PubMed ID: 20630621
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Effect of Statin Therapy on Mortality in Adult Patients with Liver Cirrhosis: An Evidence-Based Case Report.
    Agarwal R; Wisnu W
    Acta Med Indones; 2022 Jul; 54(3):491-499. PubMed ID: 36156474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.